Hematology & Oncology

Every story in hematology begins at the same source: the hematopoietic stem cell in the bone marrow first splits into two main trunks, the myeloid and lymphoid lineages, which then branch out into every number you see on your blood count. To make sense of any blood disorder, you must first hold this tree in your mind — once you have that coordinate system, you no longer need to memorize by rote why one cell type changes together with another. The single most important sentence is this: platelets and red cells share a root, arising from a common precursor called the megakaryocyte-erythrocyte progenitor. That is why, in aplasia, marrow infiltration by tumor, or chemotherapy-induced myelosuppression, hemoglobin and platelets so often fall together — never a coincidence, but the same tree cut at the same branch.

Following the common myeloid progenitor downward, one branch leads to the megakaryocyte-erythrocyte progenitor, which grows into megakaryocytes that release platelets and into erythrocytes; the other branch leads to the granulocyte-monocyte progenitor, which grows into neutrophils, eosinophils, basophils, and monocytes — which is why myeloid leukemia commonly disturbs several of these lineages at once. Lymphocytes take a separate path, arising from the common lymphoid progenitor and growing into T cells, B cells, and natural killer cells; lymphoid leukemia therefore usually does not directly implicate platelet production, unless the marrow has been crowded out of room to make other blood cells. Behind every seemingly independent blood-count number lies a connecting family tree — understand that tree, and a lab report stops being mere numbers and starts telling a story.

Erythroid growth begins in the bone marrow with the proerythroblast, passes through the basophilic and polychromatic erythroblast stages, and reaches the normoblast — remember that at this stage the nucleus has already condensed into a single dark clump and is about to be extruded, but the cell can no longer divide. Having a nucleus, then, is not the same as being able to divide; the normoblast is the last stage that still has a nucleus but no longer divides. Fix this principle firmly, and you will never again equate "nucleated" with "capable of division." After extruding its nucleus, it becomes a reticulocyte — anucleate, yet still containing RNA, so special staining reveals a reticular network. This marker of a cell that has just lost its nucleus but is not yet fully mature is the most direct evidence of whether the marrow is working overtime to restock, and the next chapter puts it to direct use when calculating the reticulocyte production index. The mature erythrocyte finally measures 6 to 8 micrometers in diameter, lives roughly 120 days, and is the most numerous cell in the blood — if you ever see an answer choice claiming the most numerous cell in the blood is the leukocyte, eliminate it immediately.

Lymphoid organs come in two kinds, and exam questions love to bury the thymus inside a trap. The primary lymphoid organs are the bone marrow and the thymus, the sites where lymphocytes are generated and mature; a germinal center, by contrast, is a reaction product that appears only after antigen meets lymphocyte, so it is seen only in the secondary organs — lymph nodes, spleen, tonsils, and Peyer's patches. The thymus has its own distinctive Hassall's corpuscles and a cortex densely packed with T lymphocytes, but it simply has no germinal center; treating the thymus as a lymphoid organ with germinal centers is the single most common point lost in histology. Peyer's patches live in the submucosa of the ileum as members of the gut-associated lymphoid tissue, formed from aggregates of lymphocytes tasked with detecting luminal antigens — they are not capillaries, not endocrine cells, and not neural tissue, and each of those distractors is designed specifically to catch anyone unsure of the material.

A platelet is a small fragment shed from the cytoplasm of a megakaryocyte, so it has no nucleus — yet it still carries microfilaments built from actin and myosin, which allow it to change shape and contract once activated, along with secretory granules prepackaged by the megakaryocyte and mitochondria that supply energy. No nucleus does not mean no organelles; a platelet is an anucleate micro-factory, not an empty shell. Mast cells and basophils are easily mistaken for each other — remember that the mast cell lives mainly in tissue, beneath the skin, in connective tissue, beneath the intestinal mucosa, waiting to be triggered by immunoglobulin E; it does not circulate in normal blood at all, so it is the cell least likely to appear on a peripheral smear. The basophil, meanwhile, is the least abundant leukocyte in the blood, but it remains a cell that does circulate.

The sinusoids of the bone marrow have a relatively intact endothelial barrier, so newly formed blood cells must actively cross the endothelium to enter the bloodstream; only the megakaryocyte extends long cytoplasmic processes directly into the sinusoidal lumen, where they are sheared into individual platelets and released — its own private shortcut. The lymphatic capillary works the opposite way: beginning as a blind-ended tube in the tissue, its endothelial cells joined by overlapping flaps, its basement membrane discontinuous or even absent, so its permeability is high and proteins and cells can enter with ease — precisely the lymphatic system's job of recovering interstitial fluid and large molecules; one-way valves appear only in the larger lymphatic vessels, never in the capillaries themselves. Last comes yellow marrow: neither damaged marrow nor fibrotic marrow, it is inactive marrow occupied by fat cells, able to revert to red marrow and resume hematopoiesis whenever the body needs it — its essence is fat, not fibrosis. Hold the hematopoietic tree as this chapter's central axis, and every question — which cells share a root, which stage first gains a nucleus, which organ does or does not have a germinal center — can be reasoned through in turn.

Anemia looks bewildering at first, but it really rests on only two axes: one, the mean corpuscular volume, tells you whether the red cell grew the way it should; the other, the reticulocyte count and production index, tells you whether the marrow is trying. Make these two cuts first, and most questions already have their cause pinned down. Why does MCV triage so cleanly? Because it reflects whether the red cell actually grew correctly. When iron is deficient, hemoglobin cannot be made, so the cell neither grows large nor stains deeply — hence microcytic, hypochromic. When vitamin B12 or folate is deficient, DNA synthesis stalls, and nuclear division cannot keep up with cytoplasmic growth, so the marrow progenitor grows into an oversized cell whose DNA has fallen behind — on the periphery, this is macrocytic anemia. A normal size usually means the marrow itself has no problem, but the cells are either being lost through bleeding, being destroyed, or the marrow itself is on strike — and this is where the second axis takes over.

Both iron deficiency anemia and anemia of chronic disease can be microcytic, and the key discriminator is ferritin. Iron deficiency means the body is genuinely depleted of iron, so ferritin falls, and the deficiency forces the liver to compensate by making more transferrin, so the total iron-binding capacity actually rises. Anemia of chronic disease, by contrast, is inflammation raising hepcidin and locking iron inside macrophages so it cannot escape, so ferritin stays normal or even rises while the total iron-binding capacity falls. Ferritin is the only marker that actually falls in iron deficiency, and that is the cleanest watershed between the two. Thalassemia is also microcytic, but its nature is entirely different — a defect in globin chain synthesis causing ineffective erythropoiesis plus hemolysis, with iron status usually normal or even overloaded, especially in the chronically transfused, where the concern is iron overload rather than the need for more iron. The discriminating tool is the Mentzer index, mean corpuscular volume divided by the red cell count: below thirteen favors thalassemia, above thirteen favors iron deficiency, because the red cell count in thalassemia is often not low and the red cell distribution width is usually normal. Finally, hemoglobin electrophoresis confirms it — in β-thalassemia, an HbA2 above three point five percent secures the diagnosis.

The most common cause of macrocytic anemia is deficiency of vitamin B12 or folate, and a neutrophil hypersegmented beyond five lobes on smear is the hallmark. To tell B12 deficiency from folate deficiency, look at the neurologic findings — only B12 deficiency causes subacute combined degeneration; folate deficiency does not. Here lies a major clinical trap: giving folate alone can correct the hematologic picture while the neurologic damage of B12 deficiency continues to worsen underneath and eventually becomes permanent. So whenever macrocytic anemia appears, you must check both B12 and folate first, or replace both together — never reflexively give folate alone.

The second axis is the production index. Looking at the raw reticulocyte percentage alone is misleading because it is diluted by the hematocrit, so it must be corrected into the production index — the formula is the reticulocyte percentage multiplied by the patient's hematocrit divided by forty-five, then divided again by a maturation correction factor, which takes a value of two at a hematocrit of twenty-three. An index above two to three means good marrow compensation — cells are being destroyed or lost, but the marrow is working hard to restock — typically hemolysis or blood loss; below two means inadequate production, typically nutrient deficiency, aplastic anemia, or marrow infiltration. Only once you have pinned down the production index do you earn the right to ask where the hemolysis is actually happening.

Hemolysis splits into intravascular and extravascular, and the difference is simply where the red cell breaks. Intravascular hemolysis is a red cell rupturing directly within the vessel, leaking hemoglobin into the plasma; haptoglobin, the scavenger protein the liver makes to capture free hemoglobin, binds it and is dragged along to the liver for breakdown, so in intravascular hemolysis haptoglobin is consumed until it becomes undetectable, and hemoglobinuria appears as well. Extravascular hemolysis is splenic macrophages engulfing the abnormal red cell whole, so hemoglobin never leaks into the plasma and haptoglobin barely falls. The representative diseases split just as cleanly — intravascular includes paroxysmal nocturnal hemoglobinuria, ABO-incompatible transfusion, and acute G6PD crises; extravascular includes hereditary spherocytosis, autoimmune hemolysis, and thalassemia. Note that hereditary spherocytosis, despite sounding dramatic with its spherocytes, is actually extravascular hemolysis — a reversed trap.

The clues to hereditary spherocytosis are an autosomal dominant family history, jaundice, gallstones, spherocytes lacking central pallor on smear, an elevated mean corpuscular hemoglobin concentration, and increased osmotic fragility; the modern first-choice diagnosis is the eosin-5-maleimide binding test. Its Coombs test is negative, and that is precisely the watershed separating it from autoimmune hemolysis, which likewise shows spherocytes but is Coombs-positive. Treatment is splenectomy, because the spleen is the site of destruction and removing it relieves the hemolysis — but at least two weeks before splenectomy the patient must receive encapsulated-organism vaccines against pneumococcus, Haemophilus influenzae, and meningococcus, and postoperative sepsis risk must be watched.

Pernicious anemia is a special form of B12 deficiency, caused by autoimmune anti-parietal cell or anti-intrinsic factor antibodies leading to intrinsic factor deficiency and an inability to absorb B12. It presents with a smooth, inflamed tongue, a mean corpuscular volume clearly above one hundred ten, and leukocytes and platelets that can fall together as well. One point that is easy to get wrong is that the red cell precursors in the marrow are actually increased rather than decreased — but because DNA synthesis is stalled, the marrow makes plenty of them yet cannot export them, a state of ineffective erythropoiesis, so the periphery remains anemic and these cells die right there in the marrow, driving up both lactate dehydrogenase and indirect bilirubin. The transfusion logic of severe β-thalassemia is not simply replacing blood but suppressing the marrow — transfuse high enough and the marrow finally falls silent, so extramedullary hematopoiesis stops acting up and hepatosplenomegaly and the hair-on-end skull do not appear; the price is iron overload, which requires a chelator given at the same time.

Paroxysmal nocturnal hemoglobinuria is the archetype of intravascular hemolysis: the mechanism is a somatic PIGA mutation that leaves the hematopoietic stem cell unable to synthesize a GPI anchor, so the cell membrane loses the complement brakes CD55 and CD59, and complement drills holes in the red cell membrane continuously, producing chronic intravascular hemolysis. The triad is hemolysis, thrombosis, and a tendency toward marrow failure, and the leading cause of death is not the anemia but the thrombosis. Diagnosis relies on flow cytometry to detect loss of CD55 and CD59, or the more sensitive FLAER assay, and treatment is the complement inhibitor eculizumab. Last comes aplastic anemia, where the marrow goes on strike entirely and all three lineages fall; the standard treatment is immunosuppression with antithymocyte globulin plus cyclosporine, and for a young patient with a suitable donor, allogeneic bone marrow transplant is the first choice — steroids alone are not first-line. The sequence of fetal hemoglobin is also frequently tested: the earliest embryonic hemoglobins are Gower I, Gower II, and Portland; by roughly ten to eleven weeks, the dominant hemoglobin is fetal hemoglobin, built from two α chains and two γ chains, and only after birth does it gradually convert to adult hemoglobin. Hold the two axes of this chapter — mean corpuscular volume and the production index — and every anemia question can be reasoned through in turn.

Leukemia questions are numerous and look scattered, but once you place them on the four-quadrant map of acute versus chronic crossed with myeloid versus lymphoid, ninety percent of them find their own place. Acute leukemia is an early cell on some differentiation pathway getting stuck, so blasts explode in number and progression is rapid; chronic leukemia is a pathway that is not completely blocked, where some station simply begins proliferating out of control, so you see cells of every maturation stage, only in explosively increased numbers, with slow progression. The blast threshold for acute leukemia is twenty percent of the marrow, a diagnostic number, and myeloid versus lymphoid is separated simply by checking Auer rods and myeloperoxidase — an Auer rod is nothing but a crystallized form of myeloid azurophilic granules, and positivity means acute myeloid leukemia, while negativity together with positive terminal deoxynucleotidyl transferase means acute lymphoblastic leukemia.

The story of chronic myeloid leukemia is the cleanest of all: the Philadelphia chromosome is simply a translocation between chromosomes nine and twenty-two producing the BCR-ABL fusion gene, which makes a fusion protein called p210 carrying continuously active tyrosine kinase activity — an accelerator stuck permanently down — so myeloid cells proliferate out of control. Imatinib was the first tyrosine kinase inhibitor marketed against BCR-ABL, plugging this accelerator switch with precision, which is exactly why it is the most classic example of targeted therapy. Clinically, the course of chronic myeloid leukemia divides into a chronic phase, an accelerated phase, and blast crisis, and tyrosine kinase inhibitors freeze most patients in the chronic phase. Among the diagnostic tools, remember that the leukocyte alkaline phosphatase score is low — precisely the opposite of the high score seen in a leukemoid reaction, which lets the two be distinguished. Two traps are worth remembering: first, do not claim chronic myeloid leukemia is unrelated to radiation — most patients have no identifiable trigger, but ionizing radiation is its one established environmental risk factor, as seen in atomic-bomb survivors and after radiotherapy; second, the single least necessary test for confirming chronic myeloid leukemia is immunophenotyping, a tool used to sort the lineage of acute leukemia, since chronic disease is adequately confirmed by karyotype and PCR alone.

Childhood acute lymphoblastic leukemia is the most common malignancy of childhood, most often of the B-cell precursor type; the mechanism is malignant proliferation of a lymphoid precursor cell displacing normal marrow, so pancytopenia from suppression of all three lineages appears together with bone pain, hepatosplenomegaly, and lymphadenopathy, and the disease is especially fond of spreading to the central nervous system and the testes. The most important prognostic factors are age and the white count at diagnosis: one to ten years old with a white count under fifty thousand carries a good prognosis, while an infant under one year or a child ten or older, or a white count above fifty thousand, carries a poor one; cytogenetically, hyperdiploidy and the twelve-twenty-one translocation producing ETV6 plus RUNX1 carry the best prognosis, while the Philadelphia chromosome, KMT2A rearrangement, and hypodiploidy carry the worst.

The role of the Philadelphia chromosome in acute lymphoblastic leukemia is entirely different from its role in chronic myeloid leukemia: in the latter, it is the disease itself; in the former, it is merely a marker of poor prognosis — don't transplant this role to the wrong place. Another frequently tested angle on Philadelphia-positive acute lymphoblastic leukemia is that it accounts for roughly twenty to thirty percent of cases in adults but only three to five percent in children, so the claim that children have a higher rate of Philadelphia positivity is false — adults actually have the higher rate. Treatment for these patients adds a tyrosine kinase inhibitor on top of chemotherapy, but there is a critically important trap here: imatinib's penetration into the cerebrospinal fluid is under one percent, so it simply cannot be used for central nervous system prophylaxis or treatment — meaning that even with a tyrosine kinase inhibitor on board, intrathecal chemotherapy must still be given; don't skip it. Every case of acute lymphoblastic leukemia requires central nervous system prophylaxis, with intrathecal methotrexate as first-line; cranial radiation has been demoted to second-line because of cognitive impairment and the risk of secondary tumors, reserved only for high-risk patients or those with existing central nervous system involvement.

Acute promyelocytic leukemia is the M3 subtype of acute myeloid leukemia: the fifteen-seventeen translocation produces the PML-RARA fusion, arresting promyelocyte differentiation at this stage, and the cytoplasm fills with granules containing tissue factor, which are released in bulk to trigger disseminated intravascular coagulation together with primary hyperfibrinolysis — hence the hallmark of prolonged prothrombin time and partial thromboplastin time, falling fibrinogen, rising D-dimer, and a bleeding tendency, with early intracranial or pulmonary hemorrhage as the leading cause of death. For this reason, the disease carries one life-saving rule: give all-trans retinoic acid the moment it is clinically suspected, without waiting for the genetic report, because all-trans retinoic acid forces the promyelocyte to mature, so granule release falls and the disseminated intravascular coagulation recedes with it; at the same time, aggressively transfuse platelets, cryoprecipitate, and fresh frozen plasma to correct the coagulopathy. Standard therapy is all-trans retinoic acid plus arsenic trioxide; low- and intermediate-risk groups may use a chemotherapy-free regimen, while high-risk groups add an anthracycline. All-trans retinoic acid alone can induce remission but relapses easily without consolidation, and it readily triggers differentiation syndrome, presenting with fever, weight gain, pulmonary infiltrates, respiratory distress, hypotension, and serosal effusions; management is corticosteroids, holding all-trans retinoic acid temporarily as needed. Early treatment must also guard against tumor lysis syndrome — hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia — prevented with hydration plus allopurinol, with rasburicase for high-risk cases, though it is contraindicated in G6PD deficiency. Finally, keep the direction straight for chronic lymphocytic leukemia: anemia or a low platelet count means advanced disease and a worse prognosis — never mistake anemia for a favorable sign; cytogenetically, an isolated 13q deletion is best, and a 17p deletion is worst because it discards the tumor-suppressor brake p53. Hold this chapter's two throughlines — the four quadrants and targeted therapy — and everything from the Philadelphia chromosome to the life-saving rule for acute promyelocytic leukemia follows the same logic: which cell, stuck at which stage, broken by what.

Lymphoma and myeloma are both malignant expressions of the B-cell family: the former is cells running out of control within the lymph node, the latter a monoclonal expansion of plasma cells within the bone marrow, and their clinical presentations could not be more different. The hallmark of Hodgkin lymphoma is the binucleate, owl-eye-like Reed-Sternberg cell; it arises from a B cell yet carries a distinctive immunophenotype, positive for CD15 and CD30 but negative for CD45, and is linked to the Epstein-Barr virus. Contiguous spread along the lymph nodes is its signature, precisely why Hodgkin lymphoma staging can use anatomic location to predict prognosis so cleanly. The most common non-Hodgkin lymphoma is diffuse large B-cell lymphoma, whose standard treatment is R-CHOP, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. The reasoning chain runs straight through: diffuse large B-cell lymphoma is of B-cell origin and expresses CD20 on its surface, so adding the anti-CD20 agent rituximab lets R-CHOP pull the cure rate upward — one of the most successful examples anywhere of combining a targeted agent with cytotoxic chemotherapy.

rituximab carries a frequently tested adverse-effect trap: latent JC virus can reactivate after treatment and trigger progressive multifocal leukoencephalopathy, the mechanism being suppression of B cells and immune surveillance, which lets the JC virus seize the opportunity to attack the oligodendrocytes of the central nervous system, presenting clinically as progressive neurologic deficits plus white-matter lesions on MRI — see this clue and the answer is progressive multifocal leukoencephalopathy. The subtypes of non-Hodgkin lymphoma are tested along the reasoning chain from chromosome to cell morphology to immunophenotype to clinical picture. Burkitt lymphoma carries the eight-fourteen translocation driving overactivation of the c-MYC gene; the pathologic "starry sky" appearance comes from macrophages that have engulfed apoptotic cells sitting embedded within a dense background of tumor cells, with a proliferation index near one hundred percent, and the endemic form is linked to the Epstein-Barr virus. Follicular lymphoma carries the fourteen-eighteen translocation driving overexpression of BCL-2, which is anti-apoptotic, making it indolent yet hard to cure. Mantle cell lymphoma carries the eleven-fourteen translocation driving overexpression of cyclin D1, with an immunophenotype that is CD5-positive but CD23-negative — the crux of distinguishing it from chronic lymphocytic leukemia. Anaplastic large cell lymphoma arises from cytotoxic T cells, CD30-positive and often accompanied by ALK positivity. Nasal NK/T-cell lymphoma arises from natural killer or T cells, marked by CD56 positivity, vascular invasion and necrosis, and a link to the Epstein-Barr virus, characteristically occurring at the nasal midline — remember the mnemonic of CD56 plus vascular destruction plus EBV plus nasal, and the two are easily told apart.

The immunophenotype of chronic lymphocytic leukemia is weak CD20 expression together with positivity for both CD5 and CD23; the way to remember it is that it is a B cell wearing a T-cell coat, because CD5 properly belongs to T cells yet is, improperly, expressed on this population of B cells. Mantle cell lymphoma is likewise CD5-positive, so the discriminator is CD23: the former is CD23-positive, the latter CD23-negative and cyclin D1-positive — get the direction of this paired comparison backward and you lose the whole question. On smear, chronic lymphocytic leukemia also shows smudge cells, fragile mature lymphocytes crushed during smear preparation, leaving behind formless cellular shadows.

Multiple myeloma is the catastrophe of monoclonal malignant plasma cell proliferation: plasma cells in the marrow secrete a monoclonal immunoglobulin, the M protein, while simultaneously causing organ damage. Every clinical finding can be derived from this single chain, and diagnosis rests on the CRAB tetrad — hypercalcemia comes from activated osteoclasts releasing calcium, renal failure comes from deposition of light chains, that is, Bence-Jones protein, compounded by hypercalcemia, anemia comes from the marrow being replaced by plasma cells, and osteolytic lesions come from osteoclast activation; other clues include an elevated erythrocyte sedimentation rate, rouleaux formation on smear, plasma cell infiltration of the marrow, and compression collapse of the vertebrae. See elderly plus anemia plus low back pain plus poor renal function plus vertebral collapse, and think multiple myeloma immediately, not simple osteoporosis — this is its most typical face.

Multiple myeloma carries two directional traps that must be spelled out clearly. On imaging, skeletal assessment in multiple myeloma should use an X-ray skeletal survey, low-dose CT, or MRI, not a nuclear bone scan, because multiple myeloma produces osteolytic lesions with brisk osteoclast activity but inactive osteoblasts, and a nuclear bone scan detects osteoblastic activity, so it gives a false negative — choosing the bone scan on this question is falling straight into the pit. In treatment, the initial therapy for multiple myeloma is not high-dose intravenous chemotherapy but a triple combination of the proteasome inhibitor bortezomib, the immunomodulatory drug lenalidomide, and dexamethasone, with eligible patients proceeding afterward to autologous stem cell transplant.

Last comes the concept of hematopoietic stem cell transplantation. Autologous transplant uses the patient's own stem cells, so there is no graft-versus-host disease, and it is used for myeloma, lymphoma, and the like; allogeneic transplant comes from another person, carrying a risk of graft-versus-host disease, but also bringing the benefit of a graft-versus-tumor effect. A frequently tested angle is that blood-type incompatibility in allogeneic transplant does not require added immunosuppression or splenectomy, because what actually determines rejection is the human leukocyte antigen — blood type affects only the red-cell side and can be managed technically. Fix in memory that human leukocyte antigen is the true key to rejection, and the question will never mislead you. Graft-versus-host disease presents as donor T cells attacking the host, producing the three cardinal signs of rash, abnormal liver function, and diarrhea. Hold this chapter's two throughlines — the B-cell family and the plasma cell — and every distinction from R-CHOP to CRAB to hematopoietic stem cell transplantation can be reasoned through in turn.

The coordinate system for every coagulation question is simply the two axes of prothrombin time and partial thromboplastin time, and memorizing one coagulation-pathway diagram lets every question be localized. The intrinsic pathway is reflected in the partial thromboplastin time, running from factor twelve through factor eleven, factor nine, and factor eight into the common pathway; the extrinsic pathway is reflected in the prothrombin time, running from factor seven plus tissue factor into the common pathway; the common pathway is factor ten, factor five, and factor two, that is, thrombin, continuing on to fibrinogen. Why can this one diagram localize almost every bleeding question? Because each coagulation factor sits on only one pathway — factor seven travels only the extrinsic pathway, so factor seven deficiency affects only the prothrombin time; factors eight and nine travel only the intrinsic pathway, so hemophilia affects only the partial thromboplastin time; while factors ten, five, two, and one sit on the common pathway, and a deficiency of any of them prolongs both times together. One clue, one pathway — trace it to the end and you have identified exactly which factor is at fault. So whenever you see a prolonged partial thromboplastin time with a normal prothrombin time, think first of hemophilia A or B, von Willebrand disease, or lupus anticoagulant.

Once the partial thromboplastin time is prolonged, the next step is the mixing test, mixing the patient's plasma with normal plasma at a one-to-one ratio and re-measuring. The logic of this maneuver is exceptionally clean: normal plasma replenishes whatever factor is missing, so the aPTT returns to normal; but if an antibody is present, it neutralizes even the replenished factor, so the aPTT remains prolonged. One small maneuver separates missing from blocked, and this is exactly the watershed for treatment direction. Corrected means a coagulation factor is deficient, typically hemophilia A or B or von Willebrand disease; not corrected means an inhibitor, that is, an antibody, is present, typically acquired hemophilia A or lupus anticoagulant.

Hemophilia A splits into congenital and acquired forms, which look identical at first glance — a prolonged partial thromboplastin time plus low factor eight — yet their treatment directions could not be more different. The congenital form is an X-linked factor eight gene defect, affecting boys, with a bleeding pattern dominated by joint bleeding and deep intramuscular hematomas; the mixing test corrects, and treatment is simply replacing factor eight; severe disease is defined as factor eight under one percent, moderate one to five, mild five to forty. The acquired form is caused by autoantibodies against factor eight, affecting postpartum women and the elderly, with a bleeding pattern of large skin bruises and soft-tissue hematomas with little joint bleeding; the mixing test does not correct, and an inhibitor titer comes back positive. The ironclad treatment rule for the acquired form is that directly replacing high-dose factor eight is often of limited benefit because the antibody neutralizes it, so bypassing agents such as activated factor seven or activated prothrombin complex concentrate are used to control bleeding before the antibody has cleared, while immunosuppression with corticosteroids plus cyclophosphamide or rituximab gradually drives the antibody down. Keep this watershed of missing versus blocked in mind, and congenital and acquired will never again be confused.

Von Willebrand disease is the most common inherited bleeding disorder. Deficiency or dysfunction of vWF disrupts hemostasis at two levels: primary hemostasis suffers from impaired platelet adhesion, because vWF is the essential bridge letting platelets stick to sites of endothelial injury; secondary hemostasis suffers because vWF is the carrier for factor eight, so a fall in vWF drags factor eight down with it. The classic tetrad is therefore menorrhagia or mucosal bleeding, plus a prolonged bleeding time, plus a prolonged partial thromboplastin time, plus a normal prothrombin time; the distinction from hemophilia is that VWD features mucosal bleeding and a prolonged bleeding time, while hemophilia is dominated by deep joint and muscle bleeding. Forgetting the prolonged partial thromboplastin time is a common way to lose points, because many people remember only that VWD is a disorder of primary hemostasis and forget that factor eight falls along with it.

Excessive anticoagulation without bleeding is another common trap. Warfarin excess without bleeding, for example an INR of five point four, is managed by holding warfarin or reducing the dose and observing, with low-dose oral vitamin K optionally added, but IV vitamin K is not immediately needed. Reflexively giving IV vitamin K just because the INR is high is wrong, because over-reversal without bleeding actually puts patients with mechanical valves at risk of thrombosis. Only in severe bleeding is four-factor prothrombin complex concentrate plus IV vitamin K used, with fresh frozen plasma as the second choice. Management of acute peripheral arterial thrombosis is primarily catheter-directed thrombolysis or surgical thrombectomy and bypass, not systemic thrombolysis, because systemic thrombolysis carries a high bleeding risk and arterial thrombi are rich in platelets and fibrin, making local treatment more effective.

Pseudothrombocytopenia is likewise a gift question: inside an EDTA collection tube, platelets clump together because of EDTA-induced agglutination, and the analyzer counts each clump as a single cell, falsely reporting a low count, yet the patient has absolutely no clinical bleeding — the giveaway that it is spurious. Confirmation comes from redrawing into a tube free of EDTA, such as sodium citrate, or checking the smear for platelet clumps, rather than using a heparin tube, which introduces its own coagulation interference. Last is the paradox of the lupus anticoagulant: one of the antiphospholipid antibodies, it interferes with phospholipid-dependent clotting assays in vitro, so the partial thromboplastin time is prolonged and the mixing test fails to correct, yet in vivo it actually promotes thrombosis — the paradox baked right into its name, called an anticoagulant yet causing clots. See a prolonged partial thromboplastin time together with recurrent thrombosis or miscarriage, and think of it; never mistake it for something that causes bleeding. Hold this chapter's throughline — the two axes of prothrombin time and partial thromboplastin time, together with the mixing test's separation of missing from blocked — and every bleeding and coagulation question can be reasoned through in turn.

The key to pediatric tumor questions is age; the key to hematologic emergencies is whether the platelet count is normal or low; the key to general oncology is the first move in an emergency. Hold these three coordinates and the clinical-scenario questions sort themselves out. Why does age separate them so cleanly? Because every tumor arises from a specific developmental cell type. Neuroblastoma arises from neural crest cells, an early cell type in neural development, so it clusters in infancy. Wilms tumor arises from nephroblasts, a residue of early kidney development, so it peaks between two and five years. Retinoblastoma arises from retinoblasts, most common within three years. Acute lymphoblastic leukemia is a lymphoid precursor cell. Hodgkin lymphoma is a differentiating B cell — the earlier the cell of origin, the earlier the tumor appears.

Acute lymphoblastic leukemia is the most common childhood leukemia, accounting for seventy-five to eighty percent, peaking at two to five years, typically presenting with fever plus bone pain plus abnormal complete blood counts plus bruising and bleeding. Acute myeloid leukemia occurs in both infancy and adolescence; in children with Down syndrome, the most common leukemia at one to three years is predominantly acute myeloid leukemia, so do not assume childhood leukemia always means acute lymphoblastic leukemia. Neuroblastoma is the most common extracranial solid tumor in children, arising from the adrenal gland or sympathetic chain, presenting with an abdominal mass crossing the midline and elevated urinary VMA and homovanillic acid; MYCN amplification means a poor prognosis. Paraneoplastic clues include dancing eyes, that is, opsoclonus-myoclonus syndrome, along with periorbital ecchymosis from orbital metastasis, resembling raccoon eyes. Wilms tumor, also called nephroblastoma, occurs at two to five years, with a renal mass that does not cross the midline and hematuria. Retinoblastoma occurs within three years, with leukocoria plus the RB1 gene. The marker trap most loves to ask: the neuroblastoma marker is VMA and homovanillic acid, not alpha-fetoprotein — alpha-fetoprotein belongs to hepatoblastoma or the yolk sac type of germ cell tumor.

The first cut in pediatric purpura is whether the platelet count is normal or low. Henoch-Schönlein purpura, that is, immunoglobulin A vasculitis, has a normal platelet count, because it is an immunoglobulin A immune-complex small-vessel vasculitis rather than a consumptive process, so the purpura comes from inflammation of the vessel wall rather than a shortage of platelets; its hallmark is palpable purpura over the lower extremities and buttocks plus abdominal pain plus joint pain plus immunoglobulin A nephritis. Immune thrombocytopenia is autoantibody destruction of platelets that often follows a viral infection; the causal chain is that the virus induces an anti-platelet immunoglobulin G antibody, the antibody binds surface glycoprotein on the platelet, and it is cleared by splenic macrophages, so the platelet count alone drops extremely low while the other cell lines stay normal. Hemolytic uremic syndrome is Shiga toxin causing endothelial injury and microangiopathy; the triad is hemolytic anemia plus falling platelets plus acute kidney injury, often following bloody diarrhea from enterohemorrhagic E. coli. Hemophagocytic lymphohistiocytosis is also easy to get backward in memory, so pin it down: platelets are low, not elevated; fibrinogen falls, not rises; while ferritin runs extremely high, triglycerides rise, and there is fever plus hepatosplenomegaly plus pancytopenia. The dividing line between Henoch-Schönlein purpura and immune thrombocytopenia is exactly the platelet count — normal in the former, extremely low in the latter.

General oncology holds onto three main lines. The carcinogenesis chain is genomic instability plus oncogene activation or tumor-suppressor inactivation, so HER2, RAS, and MYC belong to the gas-pedal category, while p53, RB, BRCA1, and BRCA2 belong to the brake category; among viral carcinogens, HPV dominates head and neck and cervical cancer, hepatitis B and C viruses dominate liver cancer, and Epstein-Barr virus dominates nasopharyngeal cancer. A few directions worth remembering: HPV-positive head and neck cancer has a better prognosis than HPV-negative disease, because the former occurs more often in younger, non-smoking patients who respond well to chemoradiation; BRCA1 carries a markedly higher ovarian cancer risk than BRCA2, a lifetime risk of roughly forty to sixty percent versus roughly ten to twenty percent; progestin is not a risk factor but a protective factor, because the core mechanism of endometrial cancer is unopposed estrogen stimulation, and progestin counteracts it — the true risks are obesity, nulliparity, polycystic ovaries, tamoxifen, and late menopause.

Tumor markers are mostly used for monitoring and rarely stand alone for screening or diagnosis — diagnosis rests on pathology. The pairings must be memorized cold: prostate cancer uses PSA, not lactate dehydrogenase, and that is a high-frequency trap; alpha-fetoprotein points to hepatocellular carcinoma and the yolk sac type of germ cell tumor; carcinoembryonic antigen is a non-specific marker used to track recurrence in colorectal cancer; CA-125 tracks ovarian cancer; CA 19-9 is for pancreatic cancer; human chorionic gonadotropin marks choriocarcinoma and germ cell tumors; lactate dehydrogenase is an indicator of lymphoma, germ cell tumor, and overall tumor burden, not a prostate cancer marker. On treatment-direction questions: stage IV renal cell carcinoma does not respond to conventional chemotherapy, and the effective options are immunotherapy, anti-angiogenic tyrosine kinase inhibitors such as sunitinib, and mTOR inhibitors; early laryngeal cancer can be treated with radiotherapy to preserve laryngeal function and avoid total laryngectomy; breast cancer with HER2 overexpression adds postoperative trastuzumab to improve overall survival.

The first move in oncologic emergencies is a guaranteed-point question. For spinal cord compression, look for back pain plus lower-extremity weakness or loss of bowel and bladder control, give immediate high-dose dexamethasone plus emergent magnetic resonance imaging, followed by radiotherapy or surgical decompression. For superior vena cava syndrome, look for facial and upper-extremity swelling, jugular venous distension, and dyspnea, usually from lung cancer or lymphoma, and manage with head-of-bed elevation plus imaging plus treatment directed at the tumor. For hypercalcemia, look for polyuria, constipation, altered mental status, and bone pain; the first step is always aggressive normal saline hydration, which is the fastest and safest; bisphosphonates treat the underlying cause but take two to four days to work; calcitonin acts quickly and can bridge the gap; and thiazides are contraindicated because they themselves retain calcium. Tumor lysis syndrome appears early in chemotherapy as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia; manage with aggressive hydration plus uric-acid lowering — rasburicase for high-risk or already-established disease, though it is contraindicated in G6PD deficiency, with allopurinol available for prophylaxis.

Last comes the antigen-antibody logic of blood typing in transfusion medicine. The key principle is that plasma naturally contains antibodies against whichever antigen it does not itself carry, so type A has anti-B, type B has anti-A, type O has both anti-A and anti-B, and type AB has neither antibody. Apply this antigen-antibody logic so that red cell transfusion looks at antigen and plasma transfusion looks at antibody, and the direction becomes clear: for red cell transfusion, type O is the universal donor, strictly speaking O-negative, while for plasma transfusion, type AB is the universal donor — the two directions run exactly opposite. So giving type A red cells to a type O patient lets the anti-A in the type O plasma tear straight through them into acute intravascular hemolysis; this must never be given even in an emergency, since the real emergency solution is to issue type O red cells, not to force through an incompatible unit. The mechanism of an acute hemolytic transfusion reaction is major ABO incompatibility plus complement, causing intravascular hemolysis; the first step in management is to stop the transfusion immediately, maintain fluids and diuresis to protect the kidneys, and notify the blood bank to recheck. Transfusion-related lung injury and circulatory overload must be told apart: both present as acute respiratory distress plus pulmonary infiltrates after transfusion, but transfusion-related acute lung injury is non-cardiogenic pulmonary edema caused by anti-human-leukocyte-antigen or anti-granulocyte antibodies, with no volume overload, diuresis ineffective, and brain natriuretic peptide normal, requiring respiratory support; transfusion-associated circulatory overload is cardiogenic pulmonary edema from transfusing too much too fast, with volume overload, diuresis effective, and brain natriuretic peptide elevated. Finally, the qualified sources for hematopoietic stem cell transplantation are bone marrow, peripheral blood stem cells, and umbilical cord blood, all rich in CD34-positive hematopoietic stem cells, while adult splenic cells are not a source, because the spleen is a lymphoid and reticuloendothelial organ and adult hematopoiesis occurs mainly in the bone marrow — this is a standard trap. The whole book closes into one sentence: look at the cell, look at the age, look at the platelet count, and the question answers itself.